[Therapy control of theophylline evening dosage in patients with sleep-related respiratory disorders--follow-up study].
We conducted a prospective study to perform classification according to responder types and follow-up during theophyllin treatment (500 mg/d) in a group of (up to now) 65 patients suffering from sleep apnoea. Changes in the apnoea index (AI) and clinical symptoms were taken as response criteria. A significant AI reduction was seen during a follow-up period of 3 months. At the last control measurement after 6 months no significant change has been detected so far. 10 patients were classified as Type I responders (improvement in initial AI 60%, over the total period at least 25%). No patient had a responder type II profile. 13 patients were nonresponders (improvement in initial AI and over the whole period not more than 25%, no improvement in the pattern of clinical symptoms). 13 patients dropped out of the trial due to non-compliance. Side effects typical of theophyllin leading to discontinuation of the treatment course occurred in 5 patients. 22 patients have not yet completed the course at the time of writing. Standardised questioning of patients showed a definite improvement in feeling tone, especially with regard to the tendency to fall asleep during the day and refreshed feeling in the morning. Nocturnal complaints occurred in only a few isolated cases. Hence, administration of theophyllin retard preparations in evening doses of 500 mg/d remains a meaningful therapeutic approach to sleep apnoea.
Grieger
E
E
Medizinische Poliklinik, Universität Marburg.
Schneider
H
H
Weichler
U
U
Peter
J H
JH
von Wichert
P
P
Voigt
K
K
D000328:Adult; D000368:Aged; D002940:Circadian Rhythm / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D011446:Prospective Studies; D012123:Pulmonary Ventilation / Q000187:drug effects; D012891:Sleep Apnea Syndromes / Q000097:blood / Q000188:drug therapy*; D013806:Theophylline / Q000008:administration & dosage* / Q000493:pharmacokinetics
D013806:Theophylline
Therapiekontrolle unter Theophyllin in abendlicher Dosierung bei Patienten mit schlafbezogenen Atmungsstörungen (SBAS)--Verlaufsbeobachtung.